Search research articles
Contact Us
Filters
Showing results (81-90 of 117) with videos related to
Page
of 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2019
Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine
Keith L Knutson, Matthew S Block, Nadine Norton, et al.
Frontiers in Immunology
|
February 14, 2022
Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy
Paige K Marty, Virginia P Van Keulen, Courtney L Erskine, et al.
Gynecologic Oncology
|
April 11, 2024
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
Lilian T Gien, Danielle M Enserro, Matthew S Block, et al.
ESMO Open
|
October 28, 2020
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
Gerardo Colon-Otero, Valentina Zanfagnin, Xiaonan Hou, et al.
Plos One
|
June 10, 2021
Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer
Tommaso Grassi, Faye R Harris, James B Smadbeck, et al.
Journal of Immunotherapy and Precision Oncology
|
February 8, 2024
Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma
Ugur Sener, Mason Webb, William G Breen, et al.
Cancer Research
|
November 16, 2014
Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer
Evanthia Galanis, Pamela J Atherton, Matthew J Maurer, et al.
Cancer Research
|
April 15, 2014
Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer
Chen Wang, Mine S Cicek, Bridget Charbonneau, et al.
Plos One
|
March 21, 2020
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations
Thomas T DeLeon, Daniel R Almquist, Benjamin R Kipp, et al.
Oncoimmunology
|
December 14, 2020
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Neeta Somaiah, Sant P Chawla, Matthew S Block, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 117) with videos related to
Sort By:
Page
of 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2019
Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine
Keith L Knutson, Matthew S Block, Nadine Norton, et al.
Frontiers in Immunology
|
February 14, 2022
Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy
Paige K Marty, Virginia P Van Keulen, Courtney L Erskine, et al.
Gynecologic Oncology
|
April 11, 2024
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
Lilian T Gien, Danielle M Enserro, Matthew S Block, et al.
ESMO Open
|
October 28, 2020
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
Gerardo Colon-Otero, Valentina Zanfagnin, Xiaonan Hou, et al.
Plos One
|
June 10, 2021
Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer
Tommaso Grassi, Faye R Harris, James B Smadbeck, et al.
Journal of Immunotherapy and Precision Oncology
|
February 8, 2024
Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma
Ugur Sener, Mason Webb, William G Breen, et al.
Cancer Research
|
November 16, 2014
Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer
Evanthia Galanis, Pamela J Atherton, Matthew J Maurer, et al.
Cancer Research
|
April 15, 2014
Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer
Chen Wang, Mine S Cicek, Bridget Charbonneau, et al.
Plos One
|
March 21, 2020
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations
Thomas T DeLeon, Daniel R Almquist, Benjamin R Kipp, et al.
Oncoimmunology
|
December 14, 2020
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Neeta Somaiah, Sant P Chawla, Matthew S Block, et al.
Page
of 12